MMP9 and cancer: Recently, carboxylate-based bivalent inhibitors more specific for MMP-9 were developed, with the aim to disrupt non-covalent MMP-9 dimerization and reduce cancer cell invasion which occurs through the MMP-9 hemopexin domain [26].